Earnings call · Apr–Jun 2026
Natco Pharma Ltd.
Apr–Jun 2026 revenue fell to ₹794 crore from ₹1,391 crore from a year earlier due to lower Lenalidomide, but EBITDA margin improved to 30.9%. PAT was ₹207 crore; management guides full-year revenue of ₹3,300–3,400 crore & PAT of ₹750 crore.
The full notes: the guidance, numbers & KPIs, strategy, outlook, risks, what analysts asked.
Premium opens every call in full: the notes, the marked passages, search & topic jumps, for every company that files a transcript.
From the company
- Scrip Code
- Rajeev Menon
- Amit Parekh
- Rajeev Nannapaneni
- Rajesh Chebiyam
Questions came from
- VamsiASK IM
- Kunal RanderiaAxis Capital
- Rashmi ShettyDolat Capital
- Abhigyan SrivastavMarcellus Investment Managers
- Tanya ChaudharyInvestec
- Arjun
- Pranav ChawlaJM AMC
- Hrishikesh Patole360 ONE Capital Markets
- Santosh
- Sahil Mahajan
- Aman
Hosted by Hrishikesh Patole of 360 ONE Capital Markets
Topics in this call
Opening remarks
Scrip Code
524816 Scrip Code: NATCOPHARM
Dear Sir
Read the whole call: 184 paragraphs, 14 analysts' questions with every answer, 6 marked passages.
Premium opens every call in full: the notes, the marked passages, search & topic jumps, for every company that files a transcript.
The transcript as the company filed it on BSE. Our own rules split it into speakers & sections; an unusual layout can trip them, so check the original PDF for anything important. Not a recommendation.